Clinical and Laboratory Investigations
Porphyria cutanea tarda, C282Y, H63D and S65C HFE Gene Mutations and Hepatitis C Infection: A Study from Southern FranceChiavérini C.a · Halimi G.b · Ouzan D.c · Halfon P.b · Ortonne J.-P.a · Lacour J.-P.a
aDepartment of Dermatology, Archet-2 Hospital, Nice, bLaboratory of Biochemistry, La Conception Hospital, Marseille, and cArnault Tzanck Institute, St-Laurent-du-Var, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: To evaluate the role of genetic factors in the pathogenesis of porphyria cutanea tarda (PCT) and their association with chronic hepatitis C. Objective: To investigate the relations between hemochromatosis gene (HFE) mutations and PCT in the south of France and their links with chronic hepatitis C virus (HCV) infection. Methods: The genotype for the C282Y, H63D and S65C mutations of HFE was determined in 33 patients with PCT, 46 patients with HCV infection but without PCT and 58 controls. Iron status and HCV, HBV and HIV serologies were studied in all patients. Results: A statistically significant increase in the C282Y mutation was found in PCT patients. No difference was found for H63D or S65C mutations. The prevalence of HCV infection was higher in PCT patients than controls. Conclusions: C282Y mutations and HCV infection but not H63D or S65C mutations are PCT-triggering or associated factors in the south of France.
© 2003 S. Karger AG, Basel
- Malina M, Stransky J, Zdarsky E: Geographical differences in prevalence of hepatitis C virus infection in PCT. Br J Dermatol 1997;136:291–292.
- Sampietro M, Fiorelli G, Fargion S: Iron overload in porphyria cutanea tarda. Haematologica 1999;84:248–253.
- Feder JN, Gnirke A, Thomas W, Tsuchiashi Z, Ruddy DA, Basava A: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399–408.
- Mura C, Raguenes O, Férec C: HFE mutation analysis in 711 hemochromatosis probands: Evidence for S65C implication in a mild form of hemochromatosis. Blood 1999;93:2502–2505.
- Feder JN, Penny DM, Irrinki A, Lee V, Lebron J, Watson N, Tsuchihashi Z, Sigal E, Bjorkman P, Schatzman R: The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472–1477.
- Trinder D, Olynyk JK, Sly WS, Morgan EH: Iron uptake from plasma transferrin by the duodenum is impaired in the HFE knockout mouse. Proc Natl Acad Sci 2002;99:5622–5626.
- Elder GH, Worwood M: Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology 1998;27:181.
- Roberts AG, Whatley SD, Nicklin S, Worwood M, Pointon J, Stone C, Elder G: The frequency of haemochromatosis associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology 1997;25:159–161.
- Roberts A, Whatley S, Morgan R, Worwood M, Elder G: Increase frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321–323.
- Stuart KA, Busfield F, Jazwinska EC, Gibson P, Butterworth L, Cooksley WG, Powell L, Crawford D: The C282Y mutation in the haemochromatosis gene and hepatitis virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998;28:404–409.
- Martinelli AL, Zago MA, Roselino AM, Filho AB, Villanova MG, Secaf M, Tavella MH, Ramalho LN, Zucoloto S, Franco RF: Porphyria cutanea tarda in Brazilian patients: Association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 2000;95:3516–3521.
- Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbetta N, Malosio I, Mattioli M, Fracanzani AL, Cappellini D, Fiorelli G, Fargion S: High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998;27:181–184.
- Enriquez de Salamanca R, Morales P, Castro M, Rojo R, Gonzalez M, Arnaiz-Villena A: The most frequent HFE allele linked to porphyria cutanea tarda in Mediterraneans is Hi63Asp. Hepatology 1999;30:819–820.
- Fargion S, Fracanzani AL, Romano R, Cappellini M, Faré M, Mattioli M, Piperno A, Ronchi G, Fiorelli G: Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: Possible explanation for iron overload. J Hepatol 1996;24:564–569.
- D’Amato M, Macri A, Griso D, Biolcati G, Ameglio F: Are His63Asp or Cys282Tyr HFE mutations associated with porphyria cutanea tarda? Data of patients from central and southern Italy. J Invest Dermatol 1998;111:1242–1243.
Dereure O, Aguilar-Martinez P, Bessis D, Perney P, Vallat C, Guillot B, Blanc F, Guilhou JJ: HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: A prospective study of 36 cases from southern France. Br J Dermatol 2001;14:533–539.
- Lacour JPH, Bodokh I, Castanet J: Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol 1993;128:121–123.
- Moran MJ, Fontanellas A, Brudieux E, Hombrados I, De Ledingjen V, Couzigou P, De Verneuil H, Enriquez de Salamanca R: Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection. Hepatology 1998;27:584–589.
- Chuang T, Brashear R, Lewis C: Porphyria cutanea tarda and hepatitis C virus: A case control study and meta-analysis of the literature. J Am Acad Dermatol 1999;41:31–36.
- Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, Kaserer K, Hackl F, Polli C, Steindl P, Penner E, Ferenci P: The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127–134.
- Lamoril J, Andant C, Bogard C, Puy H, Gouya L, Pawlotsky JM, Da Silva V, Soulé JC, Deybach JC, Nordmann Y: Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998;27:848–852.
Sampietro M, Fracanzani AL, Corbetta N: High prevalence of hepatitis C virus type 1b in Italian patients with porphyria cutanea tarda. Ital J Gastroenterol Hepatol 1997;29:543–547.
- Beutler E, Felitti V, Gelbart T, Ho N: The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329–337.
- Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercurio M, Lambrecht R: Porphyria cutanea tarda, hepatitis C, and HFE mutations in North America. Hepatology 1998;27:1661–1669.
- Roy C, Carlson E, Anderson E, Basava A, Starnes S, Feder J, Enns C: Interaction of the ectodomain of HFE with the transferring receptor are critical for iron homeostasis in cells. FEBS Lett 2000;484; 271–274.
- Camaschella C, Roetto A, Calì A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, Gasparini P: The gene TRF2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14–15.
- Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A: Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;108:619–623.
- Dereure O, Esculier C, Aguilar-Martinez P, Dessis D, Guillot B, Guilhou JJ: No evidence of Y250X transferrin receptor type 2 mutation in patients with porphyria cutanea tarda: A study of 38 cases. Dermatology 2002;204:158–159.
- Martinez PA, Bismuth M, Picot MC, Thelcide C, Pageaux GP, Blanc F, Blanc P, Sched JF, Larrey D: Variable phenotypic presentation of iron overload in H63D homozygotes: Are genetic modifiers the cause? Gut 2001;48:836–842.
- Townsend A, Drakesmith H: Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease and secondary iron overload. Lancet 2002:359:786–790.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.